The physicians, staff and patients at Mary Crowley Cancer Research are proud to have collaborated with BioVex to help develop and lead the pivotal Phase II trial of the first-of-its-kind cancer-specific, immune-enhancing herpes virus patients with melanoma just approved by the FDA.
Mary Crowley Cancer Research hosted the “Celebrate Life Sip & Shop” on Wednesday, October 21, 2015, at the home of Maria Stafford, a Mary Crowley supporter
The First Baptist Academy of Dallas paid tribute to Julia Shoemake, one of their Lower School principals on October 9th, 2015. The occasion was to recognize their own who have been diagnosed, currently fighting or who have survived breast cancer.
Ceres Barge donates a percent of the net earnings each year collected from Big Hope to the Mary Crowley Cancer Research Center in Dallas, Texas.
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology 2015 May 7;4(8):e1026529.
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Had Failed. Journal of Clinical Oncology 2015 Dec 1;33(34):4039-47.
AZD9150, a Next-Generation Antisense Oligonucleotide Inhibitor of STAT3, with Early Evidence of Clinical Activity in Lymphoma and Lung Cancer.
Phase IB Study of Lenvatinib (E7080) in Combination With Temozolomide for Treatment of Advanced Melanoma.
Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection.
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.